yspnea at rest and decreased exercise tolerance are major functional limitations for patients with cancer who develop malignant pleural effusions. Dyspnea may respond to pleural fluid drainage followed by a pleurodesis procedure that creates a symphysis of the visceral and parietal pleuras, thereby preventing pleural fluid reaccumulation.
D
yspnea at rest and decreased exercise tolerance are major functional limitations for patients with cancer who develop malignant pleural effusions. Dyspnea may respond to pleural fluid drainage followed by a pleurodesis procedure that creates a symphysis of the visceral and parietal pleuras, thereby preventing pleural fluid reaccumulation. 1 Pleurodesis may entail mechanical irritation of the pleural membranes or intrapleural instillation of chemical agents to induce pleural inflammation. Techniques for pleurodesis include thoracotomy, thoracoscopy, chest tube insertion, and thoracentesis.
Unfortunately, pleurodesis attempts fail in 10 to 40% of patients with recurrence of pleural fluid and dyspnea. 1 Because pleurodesis is associated with considerable cost and morbidity, the identification of patients who will experience an unsuccessful pleurodesis would be desirable. It has been stated that low pleural fluid pH values identify patients with a low probability of success from pleurodesis. 1, 2 Low pleural fluid pH is a marker of increased metabolic activity of intrapleural tumor collections, which corresponds to increased tumor bulk. 3, 4 Large tumor deposits prevent the apposition of visceral to parietal pleural membranes and decrease the likelihood of successful pleurodesis. 2 Some studies, 4 -10 but not all, [11] [12] [13] [14] however, have supported the association of pleural fluid pH with the outcome of pleurodesis. Moreover, if pleural fluid pH predicts the results of pleurodesis, the predictive accuracy of pH and its value compared to other tests have not been adequately quantified.
The present study determines the predictive accuracy of pleural fluid pH in predicting failure of pleurodesis, its utility compared with other pleural fluid tests and clinical factors, and the optimal pH threshold for clinical use. To address these issues, we analyzed the original patient-level data that was obtained from investigators who had studied the prognostic utility of pleural fluid pH by means of the receiver operating characteristic (ROC) and logistic regression analysis. We also evaluated the extent to which primary studies adhered to methodological standards for predictive study research and developed recommendations for the use of pleural fluid pH in managing patients with malignant pleural effusions.
Materials and Methods

Article Selection
We searched MEDLINE for pertinent articles using pH, pleural fluid, pleural effusions, pleural malignancy, malignant effusions, and pleurodesis as key words. The articles were examined to determine whether reference was made to the utility of pH for predicting pleurodesis outcome for patients with documented malignant pleural effusions. The reference lists of relevant articles were reviewed to identify additional articles and abstracts. We also queried several experts on pleural disease and the senior authors of the retrieved articles as to whether they had knowledge of additional citations or data sources related to pleural fluid pH and pleurodesis.
The investigators who were identified as data sources were asked by mail to provide their original data in spreadsheet form with the available demographic and outcome information, some of which may not have been described in their original publications. Subsequent communication was by e-mail or phone to clarify data categorizations. Investigators were asked to identify any patient observations that overlapped between different reports from their investigative groups.
The study was approved by the Institutional Review Board for Human Research of the Medical University of South Carolina.
Data Collected
Clinical characteristics of patients studied are shown in Table  1 , and data on tumor type and pleurodesis methods are summarized in Table 2 . Some other categories of data elements that were provided by investigators were excluded from analysis because they were not available from two or more patient series. Investigators provided the upper limits of the normal range for serum lactate dehydrogenase (LDH) for their laboratories, which allowed pleural fluid LDH values to be expressed as a percentage of the upper limit of the normal serum value (%LDH). Patients were excluded from analysis if they had died within 30 days of pleurodesis or if they were lost to follow-up and no information existed regarding the outcome of pleurodesis. 
Definition of Outcomes
For the purposes of this study, we defined a successful outcome as a pleurodesis that resulted in symptomatic improvement of dyspnea with complete or partial radiographic resolution of an effusion that did not require additional thoracenteses. Pleurodesis attempts that failed by this definition were classified as symptomatic failures. Because pleurodesis is palliative and low pleural fluid pH has been suggested to predict failure, symptomatic failure was considered the primary end point. Investigators supplied their data in a format that adhered to the above definitions.
Evaluation of the Study Design
The primary published studies were examined independently by two reviewers (JEH and PJN) using a structured evaluation form to evaluate the extent to which they adhered to standard design elements for predictive test research. [15] [16] [17] [18] [19] Disagreements were resolved by discussing the elements and reexamining the contested studies. The data sets supplied by the primary investigators also were examined for data collection elements that might not have been apparent in the published reports. The primary study investigators also were asked about the use of study design elements that might not have been stated in the published reports or were apparent in the data sets.
The assessed study elements were the following: (1) explicitness of the reference standard for determining pleurodesis failure; (2) use of the best available reference standard; (3) adequacy of the description of the study spectrum composition; (4) consecutive or randomly selected study patients; (5) application of the reference standard irrespective of test results (avoidance of verification bias); (6) masking of pleural fluid test results to the investigators who determined pleurodesis outcome (avoidance of review bias); (7) reporting of indeterminate reference standard results; and (8) reporting of the reproducibility of the reference standard determinations by two or more independent investigators.
Statistical Analysis
Descriptive statistics, univariate analyses, and multivariate analyses were performed on the data using computer software (JMP; SAS Institute; Cary, NC). The associations of clinical variables and pleural fluid tests with the failure of pleurodesis were determined by simple logistic regression for continuous variables and 2 or Fisher's Exact Test for categorical variables. All tests were two-tailed, with p Ͻ 0.05 considered to be statistically significant. Continuous predictors were examined by ROC analysis 20 using computer software (MedCalc, version 4.20; MedCalc Software; Mariakerke, Belgium). The areas under the curve (AUCs) of ROC plots and their 95% confidence intervals (CIs) were calculated from the ROC plots for each of the continuous predictor variables. 21 False-positive and false-negative test results were weighted equally, and test thresholds were determined by selecting the value for the variable that had the highest predictive accuracy. Additional decision thresholds for pH were examined to report their relative discriminative properties. The relative predictive accuracy of pleural fluid tests was determined by comparing the AUCs and 95% CIs for each test using patient sets for whom the results for the compared tests were available. 22 The values for AUCs also were compared using computer software (Rockit) that allowed analysis of data from all patients, including those with missing values for one of the compared tests. 23 Because the number of patients with data for each variable differed between variables, the value for the prevalence of symptomatic failure was standardized for calculation of the predictive values of tests. The prevalence of 18.5% was used for symptomatic failure because 18.5% was the prevalence of failure observed for patients with pH values who comprised the largest data set.
Variables that were found by univariate analysis to be associated with pleurodesis failure with a value for p Ͻ 0.10 were entered into a logistic regression model. Continuous variables were entered as dichotomous indicator variables with test thresholds determined by ROC analysis. Variables were removed from the model if their p values were Ն 0.05. The calibration of the predictive model to determine the degree of correspondence between predicted and observed outcomes was measured using the Hosmer-Lemeshow goodness-of-fit output from computer software (Proc Logistic, in SAS software; SAS Institute). 24 
Results
Sources of Information
The data search identified 11 articles, 4 -14 4 abstracts, [25] [26] [27] [28] and 1 letter 29 that reported outcomes of pleurodesis and pH values. All of the abstracts were excluded because their data were subsequently reported in the retrieved articles. The letter reported data that partially overlapped with a subsequent article; the investigator supplied data for these patients, which allowed the removal of duplicate data from analysis. One investigator indicated that patient-level primary data for the 131 reported patients with malignant effusions were no longer available. 12 Similarly, another investigator had not saved primary data on 20 patients undergoing pleurodesis. 4 One investigative group (F. Rodriguez-Panadero, MD; personal communication; February 3, 1998) provided additional unpublished data for 52 patients and indicated that data collection conformed to the methods of their reported studies. 7, 8 
Data
The search retrieved 570 patients for whom pleural fluid pH values were available and who had undergone pleurodesis for documented malignant effusions. All of the included patients had pleural malignancy as established by the positive results of pleural fluid cytologic studies or pleural biopsies for cancer. These patients were reported by six investigators in 10 data sources, which included one unpublished data set. [5] [6] [7] [8] 10, 11, 13, 14, 29, 30 Of these 570 patients, 137 patients were excluded from analysis because 6 died within 30 days of pleurodesis and 131 did not have outcome information because of incomplete follow-up, leaving 433 patients capable of being evaluated. The demographic features, tumor histology, tumor sites, pleurodesis techniques, and pleural fluid test results of the retrieved data sets are shown in Tables 1, 2 . No statistical differences in any data element were noted between the 137 excluded patients and the 433 patients capable of being evaluated. Not all data elements were available for each study patient. The distribution of patients across the primary investigator data sources is shown in Table 3 .
Predictors of Pleurodesis Failure
In evaluating symptomatic failure, the clinical features of pleural fluid pH (p Ͻ 0.0001), pleural fluid glucose (p ϭ 0.0002), and %LDH (p ϭ 0.0005) were associated with the failure of pleurodesis. There was no association between pleurodesis technique (p ϭ 0.3), pleurodesis agent (p ϭ 0.3), and tumor type (p ϭ 0.6) with the outcome of pleurodesis. The association of patient age with failure did not reach statistical significance (p ϭ 0.059) but was entered into the logistic regression model. The examination of the three significant predictors and patient age by ROC analysis determined test thresholds (cut-points) and the relative predictive accuracy of the tests (Table 4 Figure 1 shows the comparative ROC plots for each clinical variable; each plot is generated from all of the available data for the variable examined. The four clinical variables were entered into the logistic regression, and only pH was identified as an independent predictor of the symptomatic failure of pleurodesis. The discriminative properties of pH at different decision thresholds for predicting symptomatic failure are shown in Table 5 . The probability of pleurodesis failure increased with decreasing pH values. The pH model fit the data well according to the Hosmer-Lemeshow goodness-of-fit method based on deciles of risk (p ϭ 0.48).
None of the observed conclusions or relationships between potential predictors were altered by exclusion of the unpublished data set from the analyses.
To examine further the utility of combining tests, we calculated the discriminative properties of test combinations of pH, glucose level, and LDH level combined with an "and" rule to enhance specificity for identifying patients who would fail pleurodesis. 10 
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We used decision thresholds for each test that were determined by ROC analysis ( Table 4 ). The discriminative properties of these test combinations are shown in Table 6 .
Analysis of Study Designs
The number of assessed study design criteria that the primary studies incorporated into their methodology is shown in Table 7 . The median number of criteria incorporated by individual studies was 5 (range, 4 to 5). The study by Bilaceroglu and coworkers, 12 from which data were not available for this study, adhered to three of the eight study design elements. The study by Sahn and Good, 4 for which data were unavailable, adhered to four design elements. All of the studies used blood gas analytic instruments to measure pleural fluid pH.
Discussion
Our analysis of original, patient-level data from published studies demonstrates that pleural fluid pH has only modest (AUC, 0.671) discriminative properties for identifying patients who will experience symptomatic failure of pleurodesis. Pleural fluid pH did not have a greater predictive accuracy when compared by ROC analysis to glucose or %LDH for predicting symptomatic failure. Although pleural fluid pH had only modest discriminative properties, it was the only pleural fluid test that was an independent predictor of symptomatic failure of pleurodesis (pH decision threshold Յ7.28) when examined by multivariate analysis. Pleural fluid pH calibrated well across the range of test results, with decreasing pH values having increasing probabilities of pleurodesis failure. Neither the cell type of the malignancy nor the pleurodesis technique was associated with symptomatic failure.
This study extends previous investigations that conflict in their conclusions regarding the predictive value of pleural fluid pH. Multiple studies support the impression that pleural fluid pH predicts pleurodesis failure, 4 -10 while other investigations have not detected an association between pH and pleurodesis outcome. [11] [12] [13] [14] Each of these studies was limited, however, by small sample sizes, sensitivity to case mix, and differences in the pleurodesis techniques used. The study controlled for differences in case mix and established pleural fluid pH as the only independent predictor of outcome among the covariants available for analysis. Also, our study, in contrast to previous investigations, quantified with ROC analysis the predictive accuracy of pH, comparing its clinical utility to other pleural fluid tests and clinical factors.
Several limitations of the present investigation Figure 1 . ROC plots describing the predictive accuracy of pleural fluid pH, pleural fluid LDH levels, and pleural fluid glucose levels for predicting symptomatic pleurodesis failure.
Plots were generated using all data points available for each of the individual tests. exist, which are based primarily on the design of the primary studies. The primary studies did not adhere to several of the methodological standards recommended for predictive and diagnostic test research [15] [16] [17] [18] [19] and, consequently, presented risks for bias (Table 7) . The greatest potential source of bias exists in the absence of masking; the investigators who determined pleurodesis outcome were not blinded to the pleural fluid pH test results. An additional source of bias was the absence of a measure of the reproducibility of the subjective reference standard that defined pleurodesis outcome; all studies used only one physician to interpret patients' symptoms and radiographs in order to define the success or failure of pleurodesis. The primary studies also provided a limited number of clinical factors other than pleural fluid pH for analysis. Additional factors, such as duration of the underlying disease, duration of the pleural effusions, completion of radiotherapy or systemic chemotherapy, or presence of underlying lung conditions may alter the predictive accuracy of pleural fluid pH. Another limitation of the primary studies pertained to their comparisons of the relative predictive accuracy of pleural fluid pH, glucose level, and LDH level by analyzing data from patients who did not have results for each of the compared tests. An accurate comparison of predictive tests requires complete test data sets from all of the studied patients or data for each test from randomly selected patients. 31 Our study controlled for this limitation by entering into the ROC analysis only those patients for whom results for the compared tests were available. We also analyzed the entire data set with ROC analysis techniques that controlled for missing values and found similar estimates of relative predictive accuracy. Most importantly, the multivariate analysis using the data set with all pertinent covariants established that pleural fluid pH, while being a poor discriminator, was the only independent predictor of pleurodesis outcome.
Unfortunately, the unavailability of patient-level data from two of the retrieved primary studies may have affected the study results. 4, 12 The study by Bilaceroglu and coworkers 12 reporting 131 patients undergoing C parvum pleurodesis did not note an association between pleural fluid pH and the out- come of pleurodesis. However, their study used more restrictive patient exclusion criteria than the other primary studies and may have selected for patients (n ϭ 131) with a high likelihood of a successful pleurodesis irrespective of pleural fluid pH. This impression is supported by their 93% overall success rate for pleurodesis, which is higher than the 82% overall success rate for the studies entered into the data analysis and the 73% success rate reported for C parvum pleurodesis. 32 Also, this study adhered to a lower number of the assessed study design elements (n ϭ 3) compared with the other primary studies (median, 5; range, 4 to 5). The study by Sahn and Good 4 reported an association between pH and failure of pleurodesis in 20 patients and adhered to four study design elements. The absence of data from this report would bias our study results toward measuring a lower predictive accuracy of pH, but the overall effect on accuracy would be negligible considering the small sample size of the study. Despite the limitations of the primary studies, the findings of the present investigation are important because several authoritative sources in clinical medicine discuss the utility of pleural fluid pH for managing patients with malignant pleural effusions. 1, 2, 33 Considering the widespread use of pleural fluid pH for this purpose, the results of this study improve the clinical application of pH by providing more precise estimates of its predictive accuracy (Table 5 ) and by identifying the limitations of the data that support its use. The strengths of the present study are the adherence to methodological standards for summarizing the results of studies that evaluate predictive and diagnostic tests, 16, 34 the inclusion of unpublished data, the correspondence with primary investigators to determine the specifics of study design, and the analysis of patient-level data rather than summary descriptions of data.
The analysis of original, patient-level data is an especially important strength of our study. Most meta-analyses are performed by analyzing data available in the published literature with the use of summary statistics. This approach does not control for publication bias or allow adjustments for significant confounders. 35 We used individual patient data provided by the primary investigators, which have been shown to provide more accurate measures of outcomes than the summary analysis of aggregate data sets published in the literature. 35, 36 The inclusion of an unpublished data set within our analysis conforms to recommendations that unpublished data be included with appropriate sensitivity analyses. 37 The conclusions of our study were unchanged by the inclusion and exclusion of the unpublished data set.
On the basis of the data analysis results, the appropriate test threshold (cut-point) for predicting symptomatic failure of pleurodesis is pH 7.28. Patients with pleural fluid values at or below this threshold have an increased risk of failing to experience symptomatic improvement. The poor overall predictive accuracy of pleural fluid pH, however, indicates that its use, if it is used at all, should be limited to being an adjunctive and not a definitive test in the decision to withhold pleurodesis, especially when patients have test results near the pH threshold of 7.28. As shown in Table 4 by the positive predictive value for pH of 36.3%, only one of three patients with a pH Յ 7.28 are correctly predicted to experience a symptomatic failure after pleurodesis.
The predictive utility of pleural fluid pH may be enhanced by considering the study findings that the probability of pleurodesis failure increased with decreasing pleural fluid pH values and that the pH model calibrated well. The specificity and negative predictive value of pH for predicting symptomatic pleurodesis failure exceeded 90% and 80%, respectively, with a positive predictive value of 45.7% at very low pH values Յ 7.15. As shown by the positive predictive values listed in Table 5 , the proportion of patients expected to experience symptomatic failure of pleurodesis increased from 32 to 60% as the pleural fluid pH threshold was decreased from Յ 7.30 to Յ 7.00, respectively. The likelihood ratios generated by the study across the range of pH values (Table 5 ) can be combined with clinicians' pretest estimates that patients will fail pleurodesis to determine a posttest probability of treatment failure by the methods previously described. 38 Clinicians should recognize, however, that even at low pH values the predictive accuracy of pH is poor; only one of two patients with a pH value Յ 7.15 will be correctly predicted to fail pleurodesis. The present investigation does not support the use of pleural fluid pH values with results of pleural fluid glucose and %LDH combined in parallel "and" prediction rules, as previously suggested. 2 We found that pleural fluid pH had only marginal predictive value but that it was the only independent pleural fluid test that predicted symptomatic pleurodesis failure. This finding indicates that pleural fluid pH, glucose, and %LDH correlate to a high degree and identify largely overlapping patient subsets. This impression is confirmed by our finding that the addition of pleural fluid glucose and %LDH to pH had a negligible effect on enhancing predictive accuracy compared with pH alone (Table 6 ).
In conclusion, the available data indicate that pH has poor discriminative properties for identifying patients who will fail to experience symptomatic improvement after pleurodesis but that it is the only independent predictor of pleurodesis outcome among the baseline patient characteristics available for analysis. The low positive predictive value of pH and the limitations of the primary investigations' study designs, however, limit the utility of pleural fluid pH for managing pleural malignancies. Welldesigned studies are needed to define more clearly the predictive value of pleural fluid pH and other clinical factors for selecting patients with malignant pleural effusions for pleurodesis. Until these studies are performed, pleural fluid pH results should be used with extreme caution, if at all, in selecting patients for pleurodesis.
